Mucus permeating nanoparticulate drug delivery systems

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Mucus permeating nanoparticulate drug delivery systems
Project Number: CORDIS-103073
Project web address: Follow on CORDIS
Organization: Dechema Gesellschaft Fuer Chemische Technik Und Biotechnologie E.V., Germany, Frankfurt Am-Main
Collaborators: Cardiff University, GB
University Of Newcastle Upon Tyne, GB
Institut Jozef Stefan, SI
University Of Greenwich, GB
Universidad De Navarra, ES
Univ Innsbruck, AT
Aristotelio Panepistimio Thessalonikis, GR
Croma-Pharma Gmbh, AT
Itä-Suomen Yliopisto, FI
Thiomatrix Forschungs- Und Beratungs Gmbh, AT
Boehringer Ingelheim Pharma Gmbh & Co Kg, DE
Evonik Industries Ag, DE
Boehriger Ingelheim International Gmbh, DE
Nanomi Bv, NL
Sagetis Biotech Sl, ES
Evonik Nutrition & Care Gmbh, DE
Lek Farmacevtska Druzba Dd, SI
Merck Serono Spa, IT
Principal Investigators (PI): Andreas Förster, DE
Georgia Petridou, GR
Nick Bodycombe, GB
Jadran Lenarcic, SI
Alison Yakub, GB
Aleona Blinova, GB
Gert Veldhuis, NL
Iñigo Uriarte Pueyo, ES
Eduard Diviu, ES
Mark Knochenhauer, DE
Christian Huber, AT
Andreas Bernkop-Schnürch, AT
Janez Kerc, SI
Daniel Leblanc, IT
Pascal Badalucco, DE
Rosario Lizio, DE
Andreas Bernkop-Schnuerch, AT
Alexander Jung, DE
Timo Hartikainen, FI
 
Project Description:
The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, vaginal, buccal, pulmonary). In particular, R&D activities will be focused on the synthesis of functionalized nanocarriers capable of permeating the mucus gel layer and delivering their therapeutic payload to the epithelium. The nanocarriers will be characterized with respect to their physicochemical properties, ability to cross the mucus gel layer, in vitro and in vivo cytotoxicity. The potential of the developed nanocarriers as delivery systems for mucosal administration of macromolecules will be demonstrated via the oral delivery of peptides, oligosaccharides and oligonucleotides and the nasal delivery of a plasmid encoding for an antigen.
 
Project Terms:
nanotechnology and nanosciences
Project Title: Mucus permeating nanoparticulate drug delivery systems
Project Number: CORDIS-103073
Project web address: Follow on CORDIS
Organization: Dechema Gesellschaft Fuer Chemische Technik Und Biotechnologie E.V., Germany, Frankfurt Am-Main
Collaborators: Cardiff University, GB
University Of Newcastle Upon Tyne, GB
Institut Jozef Stefan, SI
University Of Greenwich, GB
Universidad De Navarra, ES
Univ Innsbruck, AT
Aristotelio Panepistimio Thessalonikis, GR
Croma-Pharma Gmbh, AT
Itä-Suomen Yliopisto, FI
Thiomatrix Forschungs- Und Beratungs Gmbh, AT
Boehringer Ingelheim Pharma Gmbh & Co Kg, DE
Evonik Industries Ag, DE
Boehriger Ingelheim International Gmbh, DE
Nanomi Bv, NL
Sagetis Biotech Sl, ES
Evonik Nutrition & Care Gmbh, DE
Lek Farmacevtska Druzba Dd, SI
Merck Serono Spa, IT
Principal Investigators (PI): Andreas Förster, DE
Georgia Petridou, GR
Nick Bodycombe, GB
Jadran Lenarcic, SI
Alison Yakub, GB
Aleona Blinova, GB
Gert Veldhuis, NL
Iñigo Uriarte Pueyo, ES
Eduard Diviu, ES
Mark Knochenhauer, DE
Christian Huber, AT
Andreas Bernkop-Schnürch, AT
Janez Kerc, SI
Daniel Leblanc, IT
Pascal Badalucco, DE
Rosario Lizio, DE
Andreas Bernkop-Schnuerch, AT
Alexander Jung, DE
Timo Hartikainen, FI
 
Project Categories:
Natural Sciences > Clinical Trials & Therapy > Treatment
 
Other Information:
Fiscal Year: 2012
Project Start Date: 1 April 2012
Project End Date: 31 March 2016
Project program: FP7-NMP
 
Project Funding Information:
Funding Mechanism: CP-IP - Large-scale integrating project
Year Funding Organization Total Funding, $
2012 European Research Council $12,262,352